HTI immunogen - Aelix Therapeutics
Alternative Names: DNA.HTI; HIV vaccine - Aelix Therapeutics; MVA.HTILatest Information Update: 10 Apr 2023
At a glance
- Originator Aelix Therapeutics
- Class AIDS vaccines; Epitopes; Peptide vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II HIV infections
Most Recent Events
- 19 Feb 2023 Immunigenicity and adverse event data from the phase II AELIX-003 trial presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)
- 16 Dec 2022 Gilead and AELIX Therapeutics complete a phase II (AELIX-003) trial for HIV infections (Combination therapy, Treatment experienced) in Spain (IM) (EudraCT2018-002125-30) (NCT04364035)
- 25 Jul 2022 HTI immunogen is still in phase II trial for HIV infections Combination therapy, Treatment experienced) in Spain (IM) (EudraCT2018-002125-30) (NCT04364035)